

AWARD NUMBER: W81XWH-13-1-0317

TITLE: A Computational Framework for Design and Development of Novel Prostate Cancer Therapies

PRINCIPAL INVESTIGATOR: Gaurav Bhardwaj

CONTRACTING ORGANIZATION: University of California, Davis
Davis, CA 95618-6134

REPORT DATE: Sept 2014

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE September 2014		2. REPORT TYPE Annual		3. DATES COVERED 1 Sept 2013 – 31 Aug 2014	
4. TITLE AND SUBTITLE A Computational Framework for Design and Development of Novel Prostate Cancer Therapies				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0317	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Gaurav Bhardwaj E-Mail:gauravcd34@gmail.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) UNIVERSITY OF CALIFORNIA, DAVIS Davis, CA 95618-6134				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT There is a lack of effective therapies for late-stage metastatic and castration resistant-prostate cancer. We have used multiple computational methods like molecular docking and dynamics to rapidly design and develop inhibitors targeting non-receptor tyrosine kinases, especially Etk. Etk is responsible for inducing strong survival signals in cancer cells, and thus inhibitors of this kinase may serve as effective anti-cancer therapies. In last year, we have made significant progress, and have identified many, diverse and novel inhibitors of Etk. We have also analyzed the sequences and structures of this kinase superfamily, and identified potential new target sites for drug development. Our preliminary experimental studies further support our computational observations. Overall, we have developed a computational framework for rapid drug design and development of novel anti-cancer therapies.					
15. SUBJECT TERMS Computational Drug Design, Tyrosine kinase Inhibitors, Late-stage Prostate Cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 29	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	2
2. Keywords.....	2
3. Overall Project Summary.....	2
4. Key Research Accomplishments.....	12
5. Conclusion.....	12
6. Publications, Abstracts, and Presentations.....	12
7. Inventions, Patents and Licenses.....	13
8. Reportable Outcomes.....	13
9. Training Program.....	13
10. References.....	14
11. Appendices.....	16

INTRODUCTION

Prostate Cancer (CaP) remains the second leading cause for cancer-related deaths among men in US (1). While effective therapies exist for early phases of CaP, there is no effective therapy for late metastatic stages. Previous research has shown that non-receptor tyrosine kinases, namely Etk, Btk and Src kinase, impart strong survival signals and capabilities to prostate cancer cells (2-7). These abilities are mediated via phosphorylation-mediated induction of multiple signaling pathways. Tec kinases, namely Etk are also upregulated and overexpressed in multiple cancer types, including prostate cancer (8). Given the significant role played by Tec kinases in cancer growth and progress, inhibitors of these non-receptor tyrosine kinases can serve as promising anti-cancer drug candidates. Previously, using combinatorial library approaches, our lab developed some preliminary drug candidates including CTN06, which show inhibition of kinase activity in Btk and Etk. The aim of this proposal is to supplement the combinatorial synthesis approaches with a computational framework for rapid design and development of potential inhibitors that target non-receptor tyrosine kinases, specifically Etk and Btk. Over the last year, we have made significant progress towards achieving these goals. Specifically, (i) we have used computational methods to **decipher mode of inhibition of CTN06 and CTN095**, small molecule inhibitors of Etk, and used the information derived to (ii) **computationally design, develop and virtually screen for many new potential small molecule inhibitors** of Tek kinases, and (iii) **experimentally test the designed compounds for their cell killing abilities** in prostate cancer cell lines. Further, we have used multiple sequence-based, and structure based comparative studies in the Tec-family of kinases, to **identify novel target sites**, and design strategies for targeting these sites along with our primary target of kinase activity.

KEYWORDS

Computational Drug Design, Tyrosine Kinase Inhibitors, Late-stage Prostate Cancer Therapy, Castration Resistant Prostate Cancers

OVERALL PROJECT SUMMARY

During the last funding period, we have made significant progress in computational design, virtual screening and ultimately development of multiple new Etk inhibitors. In the following section, I describe the progress made over last year, summarizing the experiments conducted, and results observed in this experiments.

Specific Aim 1: Designing and Screening Theoretical *in-silico* Drug Libraries

We have fully accomplished this specific aim. We have designed multiple large-scale *in-silico* drug libraries, and virtual screening of these libraries have identified multiple small molecule compounds that bind Etk and Btk, specifically and with high binding affinity.

Task 1a: Primary Virtual Screen of Small Molecule Libraries with AutoDock

To accomplish this task, we first had to design small molecule libraries with thousands of compounds. Since, we already had a preliminary set of binders in form of CTN06 (Figure 1a), a dual




Figure1: Chemical Structure of (A) CTN06
(B) CTA095




Figure2: Computational Docking of CTN06 to Btk. (A) Surface view of Btk docked to CTN06 after 20 ns of MD relaxation. Brown: helix C (439–452); green: activation loop helix 1 (AH1) (541–546) and activation loop helix 2 (AH2) (548–553); yellow: DFG motif (538–540); blue: Thr474; red: Cys480. (B) Cartoon representation showing predicted interactions of Btk with CTN06. Thr474, Leu408, Cys480 and Asp538 side chains are shown as sticks and colored based on residue type (red: acidic, green: polar, yellow: non-polar). DFG motif is shown in red. Figures were generated using PyMol

inhibitor of Btk/Etk; and CTA095 (Figure 1b), inhibitor of Etk and Src kinase, we decided to decipher the mode of action of CTN06 and CTN095 with *in-silico* studies, and use the information from these studies to design next-generation of Etk/Btk inhibitors.

We used computational molecular docking and dynamics to understand the molecular interactions, and thereby understand the potential mechanism of action of these small molecule inhibitors. Specifically, we used blind computational docking to scan potential binding sites for small molecule CTN06 and CTN095 on the 3D structures of Btk and Etk. Plausible binding sites and conformations were further evaluated in finer detail using Autodock4 (9, 10), and RosettaDock (10). These studies suggest that CTN06 binds with the back pocket of the kinase domain in Btk, and interacts with the physiologically important gatekeeper residue Thr474, and the DFG loop (Figure 2). This pocket had previously been identified to play significant role in kinase




Figure 3: Predicted Molecular Interactions between CTN06 and Btk. Red: Hydrophobic Interactions Green: Hydrogen-bonded residues




Figure 4: Molecular Modeling of CTA095-Etk docking. (A) Surface view of Etk docked to CTA095 after 20 ns of MD minimization and relaxation. R3 and the three-ring core docked deeper between Glycine-rich loop region (cyan) and hinge region (orange), R1 and R2 are solvent exposed. Blue: Helix C; Red: Activation Loop; Green: DFG motif (554–556); Cyan: Glycine-rich loop; Orange: Hinge Region. (B) Cartoon representation showing predicted interactions of CTA095 with the gatekeeper Thr489, DFG (554–556) motif, and Cys496. CTA095 binding stabilizes Phe555 in 'out' configuration, and affects the active state salt bridge formation between Lys445 and Glu460. Blue: Helix C; Red: Activation Loop; Green: DFG motif (554–556); Cyan: Glycine-rich loop; Orange: Hinge Region. Figures were generated using PyMol.

activity, a major functionality of these signaling molecules (11, 12). Thus, it is very likely the inhibitory activity of CTN06 on Btk is a result of the interactions with the gatekeeper residue, DFG loop and the back-pocket of ATP binding that causes conformational changes to the ATP-binding pocket. Molecular dynamics studies of these binding conformation further confirms that CTN06 binds this pocket in a stable manner. Further analysis of molecular interaction shows that the R1 group of CTN06 interaction with the gatekeeper threonine residue, while core scaffold, and R2 and R3 show interaction with the non-polar side chains in the kinase domain back-pocket (Figure 3). Docking and dynamics studies on CTN06 binding to Etk, also show a similar binding pattern for CTN06. CTN06 binds with the back-pocket of kinase domain in Etk too, and interacts with the corresponding gatekeeper Threonine residue. The back pocket in Etk is also similarly non-polar, and supports multiple hydrophobic interactions with the CTN06. Comparing the computational binding energies shows that CTN06 binds Btk stronger than Etk. This is consistent with our experimental measurements of CTN06 IC_{50} against Btk, and Etk (13). Molecular dynamics studies also support that CTN06 binds stably with Etk.

Along with the development of CTN06, we also developed CTN095, a dual inhibitor of Etk, and Src kinase. We performed the computational docking and dynamics studies to understand the interactions between Etk and CTN095. These studies show that CTA095 binds with Etk, via a similar mechanism as CTN06. CTA095 is predicted to bind the back pocket of kinase domain in Etk, interacting with the gatekeeper residue, and stabilizing the DFG loop in the inactive 'out' conformation (Figure 4) (14).

Table1: Energy Profiles of top-scoring hits from CTX-Etk virtual screening

Name	Autodock Binding Energy	Cluster Size (Max: 256)
CTX21	-12.89	194
CTX4	-12.25	223
CTX27	-11.96	209
CTX3	-11.89	231
CTX9	-12.08	159
CTX29	-11.5	250
CTX20	-11.07	255
CTX18	-10.49	246
CTX8	-10.03	219

Table2: Energy Profiles of top-scoring hits from CTG-Etk virtual screening

Name	Rosetta Interface Energy (REU)	Autodock Binding Energy
CTA095	-19.288	-7.60
CTG01	-19.287	-10.20
CTG02	-21.473	-11.25
CTG03	-16.877	-10.05
CTG04	-18.369	-9.19
CTG05	-18.582	-8.47
CTG06	-22.017	-10.85
CTG07	-18.784	-9.86
CTG08	16.297	-9.86

These studies identify a good target site for inhibiting these kinases, and provide lot of informative data on the physio-chemical property of this target sites.

Thus, these computational studies laid the foundation for further design, and development of novel inhibitors against Tec kinases. Based on the information derived from computational docking of CTN06 and CTA095, we designed *in silico* small molecule libraries, retaining the CTN06 and CTA095's 3-pronged core design, while varying the core scaffold, as well as diversifying the R1,

R2 and R3 groups. Also keeping in mind the narrow binding pocket of Btk structure, we also designed small molecule libraries with more linear architecture, expecting better shape complimentarity with these linear compounds. After generating these libraries, we performed virtual screening (fast docking using Autodock) of these libraries using Btk and Etk as targets. As it is computationally intensive to virtually screen these libraries, we scanned for binding in the previously described the backpocket of ATP binding. The results were ranked based on the Autodock binding energy, as well as the distribution of conformational clusters. Compounds that show binding energies better than CTN06




Figure5: Top-Scoring hits from virtual screening of CTX library

and CTA095 were retained for secondary screens with more sensitive and precise docking strategies using Autodock, Rosetta Ligand Docking, and final binding conformations using Molecular Dynamics.




Figure 6: Virtual Screening for Etk binding with CTG library: (A) Chemical Structures of Top Scoring Ligands (B) CTG06 bound to Etk (C) CTG02 bound to Etk

Task 1b: Secondary Screens and Identification of Next Generation of Tek kinase inhibitors

The top ranked ligands were docked again with Etk, using RosettaDock and confirmed with molecular dynamics studies. Using these studies we identified many new small molecule compounds that the same pocket as CTN06 and CTA095, but show better binding energies than our previously known small molecule inhibitors of Btk and Etk (Figure 5 and 6, Table 1 and 2). In our computational studies, CTA095-Etk docking shows an autodock binding energy and Rosetta Interface energy of -7.60 and -19.822 respectively. We have identified multiple ligands that score better than these energy terms. For example, from our CTX library, CTX21 and CTX4 shows a predicted binding energies of -12.89 kcal/mol and -12.85 respectively. Moreover, the analysis of docking conformations also shows strong correlation of bound conformations to a single major pose, further hinting at the entropic stability of the binding (Figure 4 and Table 1). From our other library that was reconfirmed using Rosetta Dock flexible docking, CTG02 shows Autodock Binding energy and Rosetta Interface Energy of -11.25 and -21.473 respectively. Docking with RosettaDock, shows a similar binding conformation profile as CTN06, but the linear nature of the conformation, leads to better shape complimentarity with the binding pocket. Another compound, CTG06, shows autodock binding energy and Rosetta Interface energy of -10.85 and -22.017 respectively. Interestingly, both CTG02 and CTG06 have the

same R1 group, but CTG02 has a different core scaffold (Figure 6). Besides the CTG and CTX compounds shown here, we have also identified multiple other variants of CTN and CTA095 compounds that show similar or better binding energy than our previously known inhibitors. In Figure 4 and 5, we have only shown the chemical structures of top hits against Etk from multiple virtual screening trials. Molecular Dynamics trajectories of 20-35 ns using NAMD (15), on all these positive hits also further confirmed that these new set of compounds bind in stable manner in the binding pocket.

Overall, using these rapid computational methods allow us to design and screen through thousands of compounds, and identify and develop drug like compounds very efficiently. Moreover, experimental data from our preliminary screens also helps us to refine our computational searches, and perform these focused design and searches. Moreover, using our computational methods we have identified a diversity of compounds, and this diversity of scaffolds and structures results is important as we head into the synthesis and experimental stages. We might lose some of positive hits to chemical synthesis problems, off-target effects and other undesirable effects, but the diversity guarantees that we will still retain a good set of novel kinase inhibitors. Overall, this goal is fully accomplished, but depending on the experimental results that we observe in next funding period, we may use these computational methods to understand the mechanisms, and further optimize these compounds

SPECIFIC AIM 2: Identifying Novel Target Sites in Etk

We have fully accomplished this specific aim. The main goal of this specific aim was to build high-resolution phylogenetic and structural models of Tec protein family, and analyze these data to identify regions that can serve as attractive targets for drug development.

Task 2a: Phylogenetic Inference of the Tec Family

To develop a high-resolution phylogenetic history of non-receptor tyrosine kinases, and study the phylogenetic relationships between individual subfamilies, we collected the protein sequences that belong to this superfamily from NCBI non-redundant (NR) database. This superfamily of non-receptor tyrosine kinases consists of 9 major families: (i) Src Family, (ii) FAK family, (iii) Csk Family, (iv) Tec Family, (v) Abl Family (vi) Syk Family, (vii) Jak Family, (viii) Fes family and (ix) Ack Family . These families have different set of protein domains, and domain architecture, but they all have the kinase domain in common. Following the generation of sequence sets, we identified conserved domains within the collected sequences using NCBI Conserved Domain Database (CDD). Following, phylogenetic tree were generated using PHYRN, a phylogenetic tool that has been previously




Figure 7: Representative Phylogenetic Tree of Tec Family inferred using PHYRN. Resampling support for deep nodes > 80%

diversity of sequence space. Pairwise alignments between the full-length (FL) sequences and the PSSM library are then used to calculate an evolutionary distance matrix(16-18). We used the conserved domains identified from CDD to generate domain specific PSSM library, which were then used to generate the phylogenetic trees of the whole superfamily. In addition to phylogenies developed by PHYRN, phylogenetic trees were generated using Multiple Sequence Alignment (MSA)-based methods. MSA was generated using MUSCLE (19, 20), followed by tree estimation using Neighbor-Joining and Maximum Likelihood methods.

We first attempted generating phylogenetic inference across the full-length sequences, using all the domains. Due to high divergence and variable nature of domain architecture, these phylogenies did not resolve properly. Therefore, we focused inferring phylogeny from the homologous kinase domain regions. This led to robust and consistent phylogenies across all the methods tested (PHYRN, MUSCLE+NJ, and MUSCLE+RAXML). Since, our drug development efforts are focused mostly on the Tec family, we herein show a representative tree of just that phylogeny in Figure 7. The phylogeny is very robust, has strong statistical support (all deep nodes show bootstrap support > 80%) and shows monophyletic relationships groupings of Etk, Itk, Tec, and Txk groups. In some methods the Drosophila members of Btk family show paraphyletic distribution. This may be because of variable evolutionary rates across these species.

Importantly, these phylogenetic studies show the highly conserved nature of the kinase domain across this large group of families, which are otherwise divergent both at the levels of sequence identity and domain representation. This further confirms the underlying difficulty of making selective inhibitors targeting this domain in the Tec family, and the entire superfamily in general. The data from these studies can be further meta-analysed to study the patterns of sequence conservation across Tec and other families as well. This will serve as crucial information in identifying regions to target within these kinases that lead to more selective inhibitors.

Task 2b: Protein Structural Modeling

Our main focus for drug development efforts has been directed towards Tec family, namely Btk, Etk and Itk members of this family, as they have been implicated in multiple cancer survival pathways. Ligand-bound crystal structures for these family members are already available in Protein Data Bank (PDB). So we did not require explicit protein structure modeling for these kinases, but most of the structures available were in various ligand-bound states. It was imperative that these structures be energy minimized in their free-form before we try to perform virtual screening against these kinases.

To achieve this, we utilized multiple different methods ranging from energy minimization using Rosetta Score function, to




Figure 9: Structural Alignment between kinase Domain of Btk (red) and Etk (Blue). Helix-C and Glycine-loop show slight differences in backbone placements

running followed by short molecular dynamics trajectories while tracking energy profiles of the structures. Specifically, after removing ligands from the PDB structures, structures were relaxed using the Rosetta Relax protocols. In addition, ligand-free structures were also relaxed in explicit solvent environment with short 5 ns trajectories using NAMD. The energy profiles of the trajectories were monitored to find the states that were energetically stable. Structures prepared in this manner were then used for our virtual screening and docking studies in Specific Aim 1 (Figure 2,3,5).

Task 2c: Comparative Sequence and Structure Studies

The data from our phylogenetic studies was further analyzed to study the sequence conservation across multiple tyrosine kinase families. As discussed previously, the kinase domain shows high sequence conservation across different families, and thus poses additional challenges to the development of drugs that are highly selective towards particular kinases. An alignment between the human Btk, Itk, and Etk shows that high identity (Figure 8) between the Btk, and Etk (Figure. Structural alignments between Btk and Etk also show that the kinase domain is highly conserved across the Btk/Etk, but there are slight variations in the back pocket, like the placement of Glycine Loop backbone that can help us develop selective inhibitors (Figure 9).




Figure 10: Domain Architecture of the Tec Family Members

Another major observation from the studies on domain architecture of these families is that Tec family is the only family among non-receptor tyrosine kinases to have a distinctive Pleckstrin Homology (PH) domain (Figure 10). This domain is important for the activation of these kinases by their interaction membrane phospholipids like PIP₃, and is especially important for cancer cell survival. Thus it may serve as an attractive target for designing and developing selective drugs for this family. In fact, we have already started working on designing peptidomimetic-based binders for the PH domain, using a novel Rosetta-based algorithm for designing cyclic peptides and/or peptidomimetics.

These studies show that kinase domain is the conserved domain across multiple families, and highlight slight differences in the binding pocket. But owing to high sequence identity and similarity of different kinase domains, designing selective inhibitors that target the kinase pocket is a challenging task. The other domains like PH domains may also be attractive targets for designing more selective inhibitors targeting the Tec family.

SPECIFIC AIM3: Experimental Validation of *in-silico* predictions

The main focus of this goal is to synthesize and experimentally validate the best hits from our virtual screening results. We are actively working on the experiments specified in this specific aim, and these experiments will be the main focus of our work over next funding period.

Task 3a: Synthesis of the Novel Small Molecule Inhibitors

We have already synthesized multiple variants of CTN06 and CTA095 that showed high binding affinity. For the variants of CTA095 and CTN06, synthesis approaches were similar to the methodology described in our previous publications (13, 14). We are currently working on the synthesis of scaffolds that are different from CTN and CTA set of compounds.

Task 3b: Effect on Cell Growth and Proliferation

After synthesis, we performed preliminary cell growth inhibition studies with our newly synthesized compounds. For cell growth inhibition studies, PC3 cells were seeded in 96 well plates, and cultured overnight, following which they were treated with 10uM drug concentration. Cell Growth was measured after 48 hrs using standard MTT assays.

Our experiments with the different CTN and CTA variants already show compounds that show growth inhibition

comparable with CTA095. In two separate preliminary studies on effect of CTN and CTA variants on

growth and proliferation of PC3 cells, (Figure 11a and 11b), we observe compounds namely CTN18 (Figure 9), and CTA201, CTA202 and CTA205 that show growth inhibition in PC3 cells that is comparable to CTA095. It is important to highlight that these compounds are not the best hits from our computational screens. For example CTA201 shows an Autodock binding energy of -10.37 kcal/mol, while our best hits show binding energies ~-12.5 kcal/mol. We expect that the CTX and CTG compounds will show better growth inhibition than even CTN06.

The tasks in this specific aim are ongoing, and in future we will focus on synthesis of all the potential inhibitors (CTX and CTG compounds) identified from our computational screens. Specifically, experiments will be focused on studying the kinase specificity, effects on kinase-mediated signaling pathways, cell growth and proliferation, in vivo efficacy and toxicity, and effects of these newly developed small molecule inhibitors on tumor growth and progression.




Figure 11: Effect of designed compounds on Cell survival in PC3 cells. A) X axis shows the absorbance at 590 nm measured at the end of MTT assay B) cell survival normalized according control treatments.

KEY RESEARCH ACCOMPLISHMENTS

- Mode of kinase inhibition by CTN06 and CTA095 was identified. CTN06 and CTA095 inhibit as a result of binding in the back pocket of kinase domain.
- Multiple novel Etk inhibitors were identified from computational design and virtual screening of drug libraries.
- Sequence and structure conservation on Tec family identified novel target sites for drug development.
- Preliminary experimental studies show that compounds developed from our computational and combinatorial approaches show inhibition of growth and proliferation in prostate cancer cell line PC3.

CONCLUSION

During last year, we have made significant progress regarding this project. We deciphered the molecular interactions between CTN06 and Btk/Etk using computational molecular docking, and we observed that CTN06 binds Btk/Etk and inhibits the kinase activity by binding with the back-pocket of kinase domain, and indirectly causing conformational changes to the ATP binding pocket. Using the information derived from studying the molecular interactions of CTN06/CTA095 binding to Tec Kinases (Btk and Etk), we developed virtual drug libraries targeted at these Tec kinases. Computational screening of these virtual libraries using Autodock and Rosetta Dock has identified novel classes of Etk inhibitors, which show good binding affinity for Etk. Molecular dynamics based studies show that these compounds bind with Etk in a temporally stable manner under the explicit solvent environment. Further, our studies on structure and sequence conservation of the non-receptor tyrosine kinase family have provided insights into the phylogenetic patterns of domain and sequence evolution within this superfamily. More importantly, it has helped identify target sites that may serve as the targets for future drug development. Taken together, we have completed Specific Aim 1 and Specific Aim 2 proposed in our original proposal.

We are currently working on synthesis of small molecule compounds that were identified from our virtual library screenings as strong binders, and their experimental validation in regards to effect on tumor cells *in vitro* and *in vivo*. Our preliminary studies on cell growth and inhibition of prostate cancer cell line, PC3, show that some of the newly developed compounds show inhibition of cancer cell growth that is comparable to the effects seen with CTN06 and CTA095. Our future studies will focus on synthesis of all the compounds identified from our virtual screen, and their experimental validation with respect to kinase specificity, *in vivo* efficacy and toxicity, and anti-tumor effects.

PUBLICATIONS, ABSTRACTS AND PRESENTATIONS

- **“Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor”** by W Guo, R. Liu, **G Bhardwaj**, JC Yang, C changou, A-H Ma, A Mazloom, S Chintalpalli, K Xiao, W Xiao, P Kumaresan, E Sanchez, C-T Yeh, CP Evans, R Patterson, KS Lam, H-J Kung, ***Cell Death and Disease*** (2014) 5, e1409

- **“Building a Haystack, and Finding the Needle: Combinatorial and Computational Approaches for Developing Anti-Cancer Therapeutics”** Presentation by **Gaurav Bhardwaj** at Institute of Protein Design, University of Washington, Seattle. (March 2014)
- **“Computational Design of Tec Kinase Inhibitors”**-Presentation by **Gaurav Bhardwaj** at the UC Davis Stand Up To Cancer (SU2C) Dream Team Meeting (October 2013)

INVENTIONS, PATENTS AND LICENSES

Nothing To Report

REPORTABLE OUTCOMES

- A paper (co-authored by me) outlining the role of CTN06 in dual inhibition of Btk and Etk, was published in journal Cell Death and Disease (see Appendix 1).
- Multiple new Etk inhibitors were identified through computational design and screening and are being developed further.

TRAINING PROGRAM

Over the last grant period, I have achieved multiple training goals specified in the original grant proposal, and continue to actively work on the training goals. These have been really crucial in my training and growth from a computational biologist to a well-rounded experimentalist, by learning various synthetic chemistry and experimental methodologies.

I have had regular meetings with my mentors to discuss the results, as well as, future directions of the projects. Besides my mentors, I have also forged very helpful collaborations at UC Davis, as well as outside the UC Davis system. For example, an active collaboration with Dr. David Baker’s lab at University of Washington, Seattle has provided immense help regarding computational support and methods development. I have also regularly attended the monthly meetings of UC Davis Prostate Cancer Affinity Group, and in the process gained insights into the other cutting-edge research going on at UC Davis and other universities regarding Castration Resistant Prostate Cancer. Besides I have also attended and presented my work at the University of California’s Stand Up To Cancer (SU2C) Dream Team meetings. Besides these, I have regularly attended the seminars and events at the UC Davis Cancer Center, and attended workshops on professional development and scientific publishing held at UC Davis.

I also attended the Evolutionary Biology Bootcamp at Simons Institute for Theory of Computing at University of California, Berkeley. This event helped me to discuss my current evolutionary inference strategies with other experts in the field. Further, I attended the Rosetta Developers Meeting at University of Washington, Seattle, and RosettaCon 2014 meeting. During these meetings, I got a chance to discuss and present my strategies on drug development and structure prediction with multiple experts and developers of the Rosetta software package.

Further, over the last funding period, I have had hands-on training on solid-phase library synthesis, one-pot chemical synthesis of small molecule compounds and libraries, and other molecular and cell biology techniques including cell toxicity assays, and confocal microscopy among others. Overall, this has been a great learning and training opportunity to expand from my computational skill set into wet lab experimentation.

REFERENCES

1. R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. *CA: a cancer journal for clinicians* **64**, 9 (Jan-Feb, 2014).
2. K. Y. Chen, L. M. Huang, H. J. Kung, D. K. Ann, H. M. Shih, The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. *Oncogene* **23**, 1854 (Mar 11, 2004).
3. Y. M. Wu, C. L. Huang, H. J. Kung, C. Y. Huang, Proteolytic activation of ETK/Bmx tyrosine kinase by caspases. *The Journal of biological chemistry* **276**, 17672 (May 25, 2001).
4. Y. T. Tsai *et al.*, Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. *Molecular and cellular biology* **20**, 2043 (Mar, 2000).
5. X. Wen, H. H. Lin, H. M. Shih, H. J. Kung, D. K. Ann, Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. *The Journal of biological chemistry* **274**, 38204 (Dec 31, 1999).
6. L. Y. Xue, Y. Qiu, J. He, H. J. Kung, N. L. Oleinick, Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. *Oncogene* **18**, 3391 (Jun 3, 1999).
7. Y. Qiu, H. J. Kung, Signaling network of the Btk family kinases. *Oncogene* **19**, 5651 (Nov 20, 2000).
8. B. Dai *et al.*, Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. *Cancer research* **66**, 8058 (Aug 15, 2006).
9. G. M. Morris *et al.*, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of computational chemistry* **30**, 2785 (Dec, 2009).
10. S. A. Combs *et al.*, Small-molecule ligand docking into comparative models with Rosetta. *Nature protocols* **8**, 1277 (2013).
11. Y. Lou, T. D. Owens, A. Kuglstatter, R. K. Kondru, D. M. Goldstein, Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. *Journal of medicinal chemistry* **55**, 4539 (May 24, 2012).
12. A. Kuglstatter *et al.*, Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. *Protein Sci* **20**, 428 (Feb, 2011).
13. W. Guo *et al.*, Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. *Cell death & disease* **5**, e1409 (2014).
14. W. Guo *et al.*, CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors. *PloS one* **8**, e70910 (2013).
15. J. C. Phillips *et al.*, Scalable molecular dynamics with NAMD. *Journal of computational chemistry* **26**, 1781 (Dec, 2005).
16. G. Bhardwaj *et al.*, PHYRN: a robust method for phylogenetic analysis of highly divergent sequences. *PloS one* **7**, e34261 (2012).
17. G. S. Chang *et al.*, Phylogenetic profiles reveal evolutionary relationships within the "twilight zone" of sequence similarity. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 13474 (Sep 9, 2008).
18. S. V. Chintapalli *et al.*, Reevaluation of the evolutionary events within recA/RAD51 phylogeny. *BMC genomics* **14**, 240 (2013).

19. R. C. Edgar, MUSCLE: a multiple sequence alignment method with reduced time and space complexity. *BMC bioinformatics* **5**, 113 (Aug 19, 2004).
20. R. C. Edgar, MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic acids research* **32**, 1792 (2004).

APPENDICES

- **“Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor”** by W Guo, R. Liu, **G Bhardwaj**, JC Yang, C changou, A-H Ma, A Mazloom, S Chintalpalli, K Xiao, W Xiao, P Kumaresan, E Sanchez, C-T Yeh, CP Evans, R Patterson, KS Lam, H-J Kung, ***Cell Death and Disease*** (2014) 5, e1409

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor

W Guo¹, R Liu^{*1}, G Bhardwaj¹, JC Yang², C Changou¹, A-H Ma¹, A Mazloom¹, S Chintapalli^{1,3}, K Xiao¹, W Xiao¹, P Kumaresan¹, E Sanchez¹, C-T Yeh⁴, CP Evans², R Patterson^{1,3}, KS Lam¹ and H-J Kung^{*,1,5}

Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies. Etk has been shown previously to provide a strong survival and metastasis signal in human prostate cancer cells, and to confer androgen independence and drug resistance. While the role of Etk in prostate carcinogenesis is well established, the functions of Btk in prostate cancer have never been investigated, likely due to the perception that Btk is a hematopoietic, but not epithelial, kinase. Herein, we found that Btk is overexpressed in prostate cancer tissues and prostate cancer cells. The level of Btk in prostate cancer tissues correlates with cancer grades. Knockdown of Btk expression selectively inhibits the growth of prostate cancer cells, but not that of the normal prostate epithelial cells, which express very little Btk. Dual inhibition of Btk and Etk has an additive inhibitory effect on prostate cancer cell growth. To explore Btk and Etk as targets for prostate cancer, we developed a small molecule dual inhibitor of Btk and Etk, CTN06. Treatment of PC3 and other prostate cancer cells, but not immortalized prostate epithelial cells with CTN06 resulted in effective cell killing, accompanied by the attenuation of Btk/Etk signals. The killing effect of CTN06 is more potent than that of commonly used inhibitors against Src, Raf/VEGFR and EGFR. CTN06 induces apoptosis as well as autophagy in human prostate cancer cells, and is a chemo-sensitizer for docetaxel (DTX), a standard of care for metastatic prostate cancer patients. CTN06 also impeded the migration of human prostate cancer cells based on a 'wound healing' assay. The anti-cancer effect of CTN06 was further validated *in vivo* in a PC3 xenograft mouse model.

Cell Death and Disease (2014) 5, e1409; doi:10.1038/cddis.2014.343; published online 4 September 2014

Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men in the United States.¹ The risk and side effects associated with current therapies, which range from impotence and incontinence after surgery to recurrence of an androgen-independent tumor after androgen ablation therapy, are severe. Tyrosine kinase inhibitors (TKIs) are among the most promising targeted therapies, most of which are directed against receptor tyrosine kinases. The outcomes of clinical trials based on TKIs as single agents have generally been modest, probably due to redundancy in receptor binding and signaling to intracellular mediators.²

The Tec family of tyrosine kinases is the second largest family of cytoplasmic tyrosine kinases. It consists of six members with tissue-specific expression patterns in normal cells. Btk is the prototype of this family of tyrosine kinases. Btk is reportedly expressed primarily in B cells, monocytes, macrophages and neutrophils,³ as well as in B-cell malignancies. In addition to being a critical effector for the B-cell

receptor,⁴ Btk engages B-cell Toll-like receptors (e.g., TLR2 and TLR4)^{5,6} and FAS.³ Btk is activated by SFK (src family kinases) and Syk, and transmits signals to PI3K and PLC-gamma, resulting in a calcium flux and the activation of NF-κB and NFATc transcriptional factors.^{7,8} The role of Btk in the immune response and hematopoietic malignancies has been well studied. Deficiency of Btk in humans leads to X-linked agammaglobulinemia (XLA).⁴ Btk has been reported as an anti-apoptotic protein in neutrophils and macrophages. Btk-deficient neutrophils have increased production of ROS and stimulation-induced apoptosis.³ Knockdown of Btk in macrophages led to increased LPS and TNF-induced apoptosis.⁶ Btk also has an important role in arthritis, leukemia and lymphoma. Several Btk inhibitors have been reported including LFM-A13, a reversible Btk inhibitor through rational design,⁹ and PCI32765, an irreversible Btk inhibitor. PCI-32765 has shown encouraging effect in clinical studies for treatment of chronic lymphocytic leukemia and in collagen-induced arthritis mouse model.^{10–12} These inhibitors also

¹Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA; ²Department of Urology, University of California Davis, Sacramento, CA 95817, USA; ³Department of Physiology and Membrane Biology, University of California Davis, Sacramento, CA 95817, USA; ⁴Department of Medical Research and Education, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan, ROC and ⁵Institute of Molecular and Genomic Medicine, National Health Research Institutes (NHRI), Miaoli County 35053, Taiwan, ROC.

*Corresponding authors: R Liu, Department of Biochemistry and Molecular Medicine, University of California Davis, 2700 Stockton Boulevard, Suite 2301, Sacramento, CA 95817, USA. Tel: +916 734 6414; Fax: +916 734 6415; E-mail: rliu@ucdavis.edu

or H-J Kung, Department of Biochemistry and Molecular Medicine, UC Davis Cancer Center, 4645 2nd Avenue, Research III, Rm 2400D, Sacramento, CA 95817, USA. Tel: +916 734 1538; Fax: +916 734 2589; E-mail: hkung@ucdavis.edu or Institute of Molecular and Genomic Medicine, National Health Research Institutes (NHRI), No. 35, Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, ROC. Tel: +886 37 246 166 ext. 31000; Fax: +886 37 586 402; E-mail: hkung@nhri.org.tw

Abbreviations: CTN06, N-(7-isobutyl-6-oxo-1-(3-(piperidin-1-yl)propyl)-5,6-dihydro-1H-imidazo[4,5-g]quinoxalin-2-yl)-4-(pyridin-4-yl)benzamide; Btk, Bruton's tyrosine kinase; Etk, Endothelial and epithelial tyrosine kinase; XLA, X-linked agammaglobulinemia; TKIs, tyrosine kinase inhibitors; CLL, chronic lymphocytic leukemia; SFK, Src family kinases; CQ, chloroquine; DTX, docetaxel; pBTK, phospho-Btk

Received 08.4.13; revised 22.6.14; accepted 13.7.14; Edited by G Ciliberto

exhibited potential in targeting multiple myeloma in the bone marrow microenvironment.¹³ Although these inhibitors greatly broadened the scope for potential Btk targeting in human diseases, reactivity of irreversible inhibitor with other proteins remains a concern. As a result, the development of a potent, reversible Btk inhibitor is highly desirable.

As described above, most reported studies of Btk focused on the hematopoietic system; however, the role of Btk in solid tumors remains unknown. By contrast, Etk (also called BMX), another member of Tec family, has been shown to be expressed in epithelial and endothelial cells, and is involved in the development or treatment resistance of several epithelial malignancies.^{14–16} It is overexpressed in human prostate cancer specimens, and provides strong survival functions in prostate cancer cells.^{17,18} Overexpression of Etk induces prostate intraepithelial neoplasia in mice,¹⁹ and knockout of Etk in an endothelial lineage decreases tumor angiogenesis and growth.²⁰ We showed previously that Etk forms a complex with Src and FAK, and that it is an effective activator of STAT3.^{21,22} In prostate cancer cells, it is activated by EGFR and erbB3,²³ as well as IL-6 and neuropeptides, leading to aberrant activation of androgen receptor.²⁴ Etk sequesters p53 and confers survival and therapeutic resistance.²⁵ In glioblastoma, Etk was found to be critical in maintaining the

self-renewal and tumorigenic potential of cancer stem cells through Stat3 activation.²⁶ Therefore, systemic inhibition of Etk may offer a synergistic anti-tumor effect. As of yet, there is no efficacious inhibitor for this kinase.

Herein, we report that Btk is also aberrantly expressed in prostate cancer. Moreover, a novel Btk and Etk dual inhibitor, CTN06, was identified. CTN06 induces autophagy and apoptosis in prostate cancer cells, and inhibits prostate cancer xenograft tumor growth *in vivo*. To our knowledge, this is the first report of the role of Btk in solid tumors, and also the first report of a novel Btk/Etk dual inhibitor with an application as an anti-cancer agent.

Results

Btk is expressed at high levels in prostate cancer. Etk has previously been reported to be overexpressed in prostate cancer, and it promotes growth, survival and angiogenesis of prostate cancer.^{19,27} Btk, the closest member of Etk in the human kinome, was mainly reported in hematopoietic cells and B-cell malignancies. The role of Btk in solid cancers remains unknown. Using a tissue microarray assay, we found that Btk is overexpressed in prostate cancer tissues. Significantly, the expression level




Figure 1 BTK is expressed in prostate cancers and cell lines. (a) The expression level of Btk in prostate cancer tissue was examined using tissue microarray. (b) The array contains 28 benign, 48 gleason 6 (CaP 6) and 46 gleason 8 (CaP 8) prostate cancer samples. (c) The antibody used was confirmed using cellblocks with PC3, PC3 with depletion of Btk by SiBtk and RAMOS cells. (d) The expression level of Etk and Btk in prostate cancer cells was examined using western blot assay. (e) Btk levels in prostate cancer cells were also measured using ELISA. (f) The antibody for tissue microarray was also confirmed using western blot with RAMOS cells and siBtk for PC3 cells, and with Daudi cells as a positive control. (g) Btk levels were further confirmed using RT-PCR. Columns, mean; bars, standard deviation, $n = 3$

of Btk correlates with the grade of prostate cancer (Figures 1a and b). The antibody used for tissue microarray was confirmed using cell blocks with RAMOS cells as a positive control (Figure 1c). In addition to the tissue microarray, the expression level of Etk and Btk in prostate cancer cells LNCaP, Du145, PC3 and immortalized normal prostate cell RWPE1 was examined using western blots. Etk was found to be high in PC3 cells, and Btk was found to be high in both Du145 and PC3 cells, a similar expression pattern compared with the tissue microarray (Figure 1d). Btk levels in RWPE1, LNCaP, Du145 and PC3 cells were further measured using ELISA (Figure 1e). The specificity of the Btk antibody used was validated by the decreased Btk level, when Btk was knocked down by siRNA targeting Btk in PC3 cells, as well as in RAMOS cells which served as a positive control (Figure 1f). The elevated mRNA levels of Etk and Btk in those cells were also observed, using real-time RT-PCR, which indicates the overexpression of Etk and Btk in prostate cancer cells is at least in part at the transcriptional level (Figure 1g).

Simultaneous knockdown of Etk and Btk inhibits prostate cancer cell growth. Etk knockdown has been reported to slow down prostate cancer cell growth. A similar result was observed in PC3 cells with Etk knockdown (Figure 2a). To explore the role of Btk in prostate cancer cell growth, the Btk level in PC3 prostate cancer cells was knocked down using siRNA. Btk knockdown in PC3 cells showed a similar inhibitory effect on prostate cancer cell growth as compared with Etk knockdown. Simultaneous knockdown of Etk and Btk resulted in a much greater inhibitory effect on prostate cancer cell growth when

compared with Etk or Btk knockdown alone (Figure 2a). In stark contrast, RWPE1, the immortalized normal prostate cell line, is resistant to Etk and Btk knockdown (Figure 2b), indicating an Etk/Btk 'addiction' of the prostate cancer cells. The effect of Btk to prostate cancer cell growth was further examined in PC3 cells and Du145 cells using SiBtk and LFM-A13, a known Btk inhibitor. Both approaches inhibited prostate cancer cell growth at a similar level, further confirming an important role of Btk in prostate cancer cell growth (Figure 2c).

CTN06 as a dual inhibitor against Btk and Etk tyrosine kinases. Having identified a tumor-specific role of Btk and Etk in prostate cancer, we attempted to develop inhibitors targeting this family of kinases. Through screening a 9600-diversity combinatorial solution phase small molecule library, hit compounds with inhibitory activities against Etk were discovered. Subsequent optimization led to the identification of CTN06 (Figure 3a). To determine the substrate specificity of this compound, purified Etk, Btk, Src and Mer were incubated in a kinase reaction buffer with CTN06 (0–10 μ M) in the presence of 33 P-labeled ATP and a peptide (YIYGSFK), previously shown to be an excellent substrate for both Btk and Src family kinases. The kinase activity was measured using the thin-layer chromatography (TLC) technique. CTN06 was found to be an even more potent Btk inhibitor with an IC_{50} of ~ 50 nM compared with Etk ($IC_{50} \sim 200$ nM) (Figure 3b). Inhibition was observed in a concentration-dependent manner. Src ($IC_{50} \sim 5$ μ M) and Mer ($IC_{50} > 10$ μ M) were significantly more resistant to CTN06 inhibition (Figures 3b and c).




Figure 2 Both Btk/Etk (BMX) contribute to proliferation of prostate cancer cells. (a and b) The expression of Etk and Btk in PC3 and RWPE1 cells was knocked down using the corresponding siRNA. The growth of the knockdown cells was measured using MTT assay. (c) The effect of Btk on prostate cancer cell growth was further confirmed using siBtk and LFM-A13 (50 μ M) in PC3 and Du145 cells. Columns, mean; bars, standard deviation, $n = 3$

In addition to the Btk family tyrosine kinases, the inhibitory activity of CTN06 against other tyrosine kinases, including Itk, Lyn, Axl, Mer, EGFR and Abl, was investigated using the TLC assay. CTN06 appears to have the strongest activity toward Btk and Etk, followed by Itk, another member in the same family. No significant inhibitory activity toward any other kinases was observed (Figure 3d).

The inhibitor specificity is supported by the molecular docking studies. CTN06 is found to bind to the pocket of the ATP binding site with a binding energy of -11 kcal/mol (Figures 3e and f). Previous studies have shown kinase inhibitors that bind to this pocket.^{28,29} Further analysis through molecular dynamics reveals that CTN06 interacts with the 'gatekeeper' residue T474. CTN06 also interacts with the side




Figure 3 CTN06 is a potent Etk and Btk dual inhibitor. **(a)** Chemical structure of CTN06. **(b)** The potency of CTN06 to Btk, Etk, Src and Mer was measured using TLC to identify 32 P-phosphorylated peptide substrate. Purified TKs (20 nM), CTN06 (0–10 μ M) and the peptide substrate (YIYGSFK) were incubated with 32 P-ATP in a kinase reaction. The resulting product was analyzed on a TLC plate. **(c)** The intensity of the radioactive spot was measured using densitometer. **(d)** Summarization of the kinase inhibition profile of CTN06. Columns, mean; bars, standard deviation, $n=3$. Molecular docking of CTN06 to Btk. **(e)** Surface view of Btk docked to CTN06 after 20 ns of MD relaxation. Brown: helix C (439–452); green: activation loop helix 1 (AH1) (541–546) and activation loop helix 2 (AH2) (548–553); yellow: DFG motif (538–540); blue: Thr474; red: Cys480. **(f)** Cartoon representation showing predicted interactions of Btk with CTN06. Thr474, Leu408, Cys480 and Asp538 side chains are shown as sticks and colored based on residue type (red: acidic, green: polar, yellow: non-polar). DFG motif is shown in red. Figures were generated using PyMol

chains of C480, which is a residue unique to Btk when compared with other kinases. Previous studies have shown that only 8 kinases out of 491 that show T474 and C480 combination at these positions.²⁸ Molecular dynamics studies reveal that CTN06-Btk binding is stable. We analyzed the molecular dynamics trajectories (Supplementary movie) and plotted putative hydrogen bonding and hydrophobic interactions between CTN06-Btk using LigPlot+ (Supplementary Figure S2). CTN06 putatively forms multiple hydrophobic interactions with side chains of the pocket. The R₁ group interacts with T474, as well as the DFG motif that is important for kinase activity. R₂ and the three-ring core interact with the Glycine-rich loop region, as well as C480. Overall, computational studies show that CTN06 binds to Btk in a stable manner, and the interactions with the back pocket, gate-keeper threonine and the DFG motif lead to its kinase inhibitory properties.

CTN06 preferentially inhibits the growth of malignant prostate cells. To determine the effect of CTN06 on proliferation, a panel of cancer cell lines including LNCaP, Du145, PC3 and the immortalized normal prostate epithelial cell line, RWPE1, were incubated with CTN06 and their proliferation was measured using the MTT assay. CTN06 was very effective in inhibiting the growth of prostate cancer cells (PC3, Du145 and LNCaP), while RWPE1 was much more resistant to CTN06. The ability of CTN06 to inhibit Btk activation, based on phospho-Btk (pBTK) expression in those cells was confirmed using western blot (Figure 4a).

CTN06 induces autophagy in prostate cancer cells. Previously, we showed that the Src inhibitor AZD0530 induces autophagy in prostate cancer cells, which contributes to apoptosis resistance and diminishes the efficacy of the Src inhibitor.³⁰ To determine whether CTN06 can trigger autophagy, PC3 cells stably transfected with GFP-LC3 were treated with CTN06 and then examined under fluorescence microscopy. After 2 and 24 h treatment with CTN06, these cells yielded extensive, distinct 'puncta' autophagosome morphology, whereas vehicle treatment did not. The ability of CTN06 to induce autophagy in PC3 cells was further confirmed by the conversion of endogenous LC3-I to the lipidated LC3-II forms. Addition of chloroquine (CQ), an autophagy blocker and lysosomal disruptor, resulted in the accumulation of larger autophagosomes, suggesting CTN06's effect is on the induction of autophagosome formation (Figure 4b).

CTN06 induces apoptosis in prostate cancer cells. To determine whether the growth inhibition induced by CTN06 on prostate cells was due to apoptosis, flow-cytometric analysis was carried out. Following treatment with CTN06 for 24 h, a dose-dependent accumulation of a 'sub-G1' fraction was observed using propidium iodide (PI) staining. Data based on Annexin-V reactivity also indicated a dose-dependent increase in apoptosis of PC3 cells following treatment with CTN06 (Figure 4c). The 'sub-G1' fraction only measures dead cells with DNA content loss, which may explain why it was less than the percentage of apoptotic cells measured by Annexin-V.

CTN06 inhibits prostate cancer cell migration. Tec-family tyrosine kinases have been shown to have an important role in cellular movement and cancer metastasis. To explore the ability of CTN06 to inhibit cell migration, 'wound healing' of PC3 cells was measured following treatment with CTN06. As shown in Supplementary Figure S3, 'wound healing' of PC3 cells was greatly inhibited by CTN06 after 16 h. These results suggest that CTN06 has the ability not only to suppress prostate cancer cell growth, but also to inhibit cell migration, implicating CTN06 as an anti-metastasis agent.

CTN06 inhibits the phosphorylation of Btk, Etk and the downstream signal PLC γ 2, Stat3, Akt in prostate cancer cells. The inhibitory activity of CTN06 against phosphorylation of Etk and Btk in intact cells was examined by western blot. Btk as well as Etk phosphorylation in PC3 cells were significantly inhibited at 0.5 and 2 μ M. The pPLC γ 2 inhibition is likely to result from Btk inhibition. A selective target for Etk is STAT3,³¹ whose phosphorylation is also inhibited by CTN06, so is Akt, another important downstream effector of Etk (Figure 5). Interestingly, Src phosphorylation was greatly inhibited in cells following treatment with CTN06 compared with kinase inhibition assay. This may be due to inhibition of Etk, which has been shown to cross activate Src.²¹

CTN06 modulates cancer-related miRNAs. Many miRNAs have been reported to have a role in carcinogenesis. To explore whether CTN06 modulates miRNAs, 272 miRNA levels in PC3 cells were examined using a microarray assay following treatment with CTN06. Among them, 22 exhibited alterations >2 folds, for most of which, there are no established functions in oncogenesis (Supplementary Figure S4a). A number of them, however, are known to possess oncogenic and tumor suppressive properties. We found that those miRNAs with tumor suppressive properties were generally upregulated, and those with oncogenic properties were downregulated following treatment with CTN06 (Supplementary Figure S4b).^{32–43} For instance, Mir-132, which is upregulated 29.9 folds following treatment with CTN06, has been reported to be downregulated by promoter methylation in prostate cancer cells. On the other hand, CTN06 downregulates Mir-421 (– 46.3 folds), which has been reported to downregulate ATM, a pro-apoptotic protein.⁴²

CTN06 downregulates oncogenic-related genes. To further explore the mechanism of anti-cancer effect of CTN06 in prostate cancer cells, cDNA microarray assay was performed in PC3 cells following treatment with CTN06. Among the 772 genes examined, 57 genes were down-regulated > 2 folds. Interestingly, 25 of which are oncogenic-related genes (Supplementary Figure S4c). Among those genes, Met, which is downregulated 2.1 folds following treatment with CTN06, has been reported to be constitutively activated in PC3 cells, and inhibition of Met led to significant inhibition of PC-3 cell proliferation, clonogenicity, migration and invasion.⁴⁴ MYCBP, which is downregulated 2.1 folds by CTN06, is a positive regulator of Myc. Downregulation of MYCBP by miR22 suppresses oncogenic Myc activity.⁴⁵

CTN06 has higher potency to inhibit prostate cancer cell growth compared with other kinase inhibitors. To further




Figure 4 CTN06 induces autophagy as well as apoptosis in prostate cancer cells. (a) Growth inhibition of CTN06 to LNCaP, Du145, PC3 prostate cancer and normal prostate (RWPE1) cells. Cells were seeded at 5000 cells/well in 96-well plate overnight and treated with CTN06 at the indicated concentrations. The cell viability was measured using MTT assay after 72 h. Columns, mean; bars, standard deviation, $n = 3$. Inhibition of Btk by CTN06 (0.5 μM) in those cells was measured using western blot. (b) Induction of autophagy in PC3 cells by CTN06. PC3 cells were stably transfected with GFP-LC3 and were grown in 6-well plate to 50% confluence and treated with CTN06. Autophagy was visualized by GFP-LC3 'puncta' at 2 and 24 h and immunoblot of endogenous LC3 isoforms 24 h after treatment. (c) Induction of apoptosis of PC3 cells following treatment with CTN06. PC3 cells were seeded at 10^6 cells/ml (2 ml) in a 6-well plate overnight and then treated with CTN06 at the indicated concentrations for 24 h. Apoptosis was analyzed using PI staining as well as Annexin V-FITC apoptosis detection kit. Columns, mean; bars, standard deviation, $n = 3$. In all, 0.5 and 2 μM are significantly different from 0 μM (* $P < 0.05$, one-way ANOVA with Tukey test for pairwise comparison)

explore the potency of CTN06 to prostate cancer cells, growth inhibitory activity of CTN06 to PC3 cells was compared with other kinase inhibitors including saracatinib (AZD0530), sorafenib, AG1478, 3ATA and LMF-A13. At 2 μM , CTN06 showed the highest potency to inhibit PC3 cell growth followed by sorafenib (Figure 6a). This result indicated that CTN06 is a potent inhibitor of prostate cancer cell growth.

CTN06 as a chemo-sensitizer. Our initial studies indicated that CTN06 has good cytotoxicity toward a panel of prostate cancer cells. To examine whether a Btk and Etk dual inhibitor works effectively as a chemo-sensitizer, PC3 cells were co-treated with CTN06 (0.25 μM) and the autophagy inhibitor CQ (10 μM), or docetaxel (DTX) (2 ng/ml). Growth inhibition was determined using an MTT assay after 72 h. Interestingly,




Figure 5 Inhibition of cell signaling in PC3 cells following treatment with CTN06. Cells were grown in 100-mm plate to 50% confluence and treated with CTN06 at the indicated concentrations. Cells were harvested after 12 h. pEtk, Etk, pBtk, Btk, pSrc, Src, pPLC γ 2, PLC γ 2, pStat3, Stat3, pAkt, Akt, pERK and ERK levels were measured using the corresponding antibodies by western blot. One of three similar experiments depicted

a synergistic effect of CTN06 was observed when prostate cancer cells were co-treated with CQ. In the case of DTX co-treatment, less of a synergistic effect was observed when CTN06 and DTX were added to the cells at the same time, while a striking synergistic effect was observed when cells were treated with DTX for 24 h before treatment with CTN06 (Figure 6b). Annexin-V and PI staining further confirmed that combination of CTN06 and CQ induced apoptosis (Figure 6c). This suggests that CTN06 is a chemo-sensitizer, and blocking of autophagy by CQ promotes CTN06-induced cell death.

CTN06 inhibits PC3 xenograft tumor growth *in vivo*. Given the *in vitro* activity of CTN06 against prostate cancer cells, it is important to validate these results *in vivo*. PC3 cells were injected subcutaneously to nude mice. The mice were treated with vehicle (control) or CTN06 at 10 mg/kg daily via IP injection. As shown in Figures 7a and b, CTN06 decreased PC3 xenograft tumor growth without significant toxicity. Furthermore, Ki67 staining indicated that CTN06 inhibited tumor growth activity and cleaved caspase 3 staining indicated that it also induced apoptosis (Figure 7c). Western blot of LC3I to LC3II conversion suggested autophagy induction in PC3 xenograft tumors by CTN06 (Figure 7d).

Discussion

Tyrosine kinases have become important targets for drug development. Powerful combinatorial chemistry approaches and high-throughput screening assays have led to successful identification of many kinase inhibitors.^{46–48} Our previous work indicated that Etk is complexed with Src and FAK, and




Figure 6 CTN06 as a chemo-sensitizer. (a) Comparison of CTN06 with other kinase inhibitors. PC3 cells were seeded at 5000 cells/well in 96-well plates overnight and treated with CTN06 or the other kinase inhibitors including AZD0530, sorafenib, AG1478, 3ATA and LMF-A13 at 2 μ M. The cell viability was measured using MTT assay after 72 h. (b) Growth inhibition of CTN06 and in combination with 10 μ M chloroquine (CQ) or 2 ng/ml docetaxel (DTX) to PC3 human prostate cancer cells. Cells were seeded at 5000 cells/well in 96-well plate overnight and pretreated with the corresponding co-treatments for 1 h, then treated with 0.25 μ M CTN06. The cell viability was measured using MTT assay after 72 h. (c) The apoptotic effect of CTN06 in combination with CQ to PC3 cells was further measured using Annexin-V and PI staining and flow cytometry. Columns, mean; bars, standard deviation, $n = 3$

has an important role in apoptosis, angiogenesis and metastasis of prostate cancer cells.²² Etk activation is a compensatory response to androgen deprivation, implicating its overexpression in castration-resistance transition.⁴⁹ In addition, Etk interacts with p53 and controls the apoptosis pathway.²⁵ Etk's role in other solid tumors including bladder cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and breast cancer is well established.^{14–16,50} Etk has recently been implicated in the self-renewal and tumorigenic potential of glioblastoma stem cells.²⁶ Etk, highly expressed in endothelial cells, has been shown to be a critical tyrosine kinase for angiogenesis and tumor growth.¹⁸ All these findings




Figure 7 Inhibition of PC3 xenograft tumor growth by CTN06. 2×10^6 PC3 cells were injected subcutaneously to nude mice. The tumors were grown to the indicated size and the mice were randomly divided into two groups (8 mice/group). The control group was treated with vehicle. The treatment group was treated with CTN06 at 10 mg/kg daily via IP injection. (a and b) The tumor size and body weight were measured once a week. Marks, mean; bars, mean; $n = 8$ ($*P < 0.05$, one-way ANOVA with Tukey test for pairwise comparison). (c and d) The tumor samples were further analyzed for Ki67 and cleaved caspase 3 using immunohistochemistry and LC3I to LC3II conversion using western blot

point to Etk as an appropriate therapeutic target. Yet, surprisingly little is known about Etk selective inhibitors. One recent report showed that an EGFR inhibitor, CI-1033, inhibits Etk at a sub-micromolar level via irreversible modification of a conserved cysteine residue.⁵¹ In this study, we set forth to identify a selective inhibitor for Etk.

Perhaps, the most striking observation of this study is the discovery that not only Etk is involved in prostate carcinogenesis, but also its close relative Btk. Previously, Btk was mainly reported in B cells and B-cell malignancies. Btk inhibitors have been developed for the benefit of treating hematopoietic diseases. The role of Btk in solid tumors remains totally unknown. Here, we report that Btk is aberrantly expressed in prostate cancer tissues and cells. The Btk expression level increases with the higher grade tumors, and in the prostate cancer cell lines, it is expressed at a much higher level in androgen-independent cell lines than androgen-sensitive LNCaP cells or immortalized normal epithelial cells. Indeed, both Btk and Etk have a distinct but overlapping role in prostate cancer growth and survival. Knockdown of individual kinases attenuates the growth of PC3 cells, but simultaneous knockdown has greater effects. Thus, while we were screening for Etk inhibitors, we also look for those that inhibit both, and were able to identify CTN06 that inhibits both Etk and Btk and to a lesser extent, Itk. To our knowledge, this is the first selective Btk/Etk dual inhibitor reported to date.

CTN06 belongs to a novel class of reversible kinase inhibitors with a chemical structure distinct from other known TKIs. This inhibitor is most potent in inhibiting Btk followed by Etk. Compared with known Btk inhibitors, the inhibitory potency of CTN06 against Btk is about 100-fold stronger than LFM-A13 which is a reversible Btk inhibitor (Figure 3b). There

are few Etk inhibitors reported so far. CI-1033 is a potent irreversible EGFR inhibitor with moderate Etk inhibition, but clinical study reported that CI-1033 is associated with severe toxicity.⁵² Therefore, a reversible Etk inhibitor such as CTN06 may have advantages and is probably less toxic. Treatment of PC3 cells with CTN06 resulted in the decrease in phosphorylation of Btk and Etk, as well as the downstream signals PLC γ 2, Stat3 and Akt. Interestingly, Src phosphorylation was greatly inhibited in cells following treatment with CTN06 compared with kinase inhibition assay. This is likely due to inhibition of Etk, which has been shown to crossactivate Src.²¹ Significantly, CTN06 has much less effect on the growth of the immortalized normal prostate cell RWPE1, consistent with the Btk/Etk knockdown experimental results (Figure 2). While PC3 and DU145 have much higher expression level of Btk, LNCaP expresses both Etk and Btk about the same level as RWPE1; yet LNCaP appears to be more sensitive to CTN06 than RWPE1, suggesting that prostate cancer cells have adapted to the Etk/Btk pathway for growth and survival, much more so than normal prostate epithelial cells. This provides a strong rationale for targeting Btk/Etk pathway in prostate cancer cells. In addition, we and others previously reported that Src inhibitors such as saracatinib (AZD0530) or dasatinib, while effective in inhibiting metastasis, are generally not inducers of apoptosis, which is in part due to their ability to induce autophagy.^{30,53} By contrast, CTN-06 induces a high level of apoptosis, despite its ability to induce autophagy. This is likely due to the fact that Etk also interacts with and inactivates p53. Overexpression of Etk in prostate cancer cells is known to confer apoptosis resistance to androgen deprivation and photodynamic therapy.^{17,49} Given the anti-apoptotic role of Btk in B-cell malignancies, it is likely that

inhibition of Btk also contributes to the induction of apoptosis in prostate cancer cells. In addition, the effects of CTN06 on miRNAs could in part account for its ability to induce apoptosis in prostate cancer cells. This suggests that dual inhibitors of Btk/Etk, which connects to Src pathway, may offer a more effective alternative to Src inhibitors in terms of cell killing. Indeed, we found CTN06 is a much more effective growth inhibitor than AZD0530 (Figure 6a) as well as other currently approved anti-cancer drugs.

The finding that autophagy inhibitor CQ further enhances the apoptosis-inducing effect of CTN06 suggests that here, like that in the case of other tyrosine kinase inhibitors,³⁰ autophagy contributes partially to the survival of CTN06-treated cells. Thus, autophagy inhibitor may be considered to enhance the efficacy of this compound. CTN06 is also a chemo-sensitizer and showed synergistic effect with DTX, indicating its potential role in combination therapy for prostate cancer. Interestingly, the sequence of its application is important. DTX followed by CTN06 is more effective than the reverse. This is understandable, as DTX action requires the cell-cycle movement to G2/M phase, which may be impeded if CTN06 was added first. Finally, consistent with Etk's role in cellular movement and as a co-activator of FAK,²¹ CTN06 was found to inhibit migration of prostate cancer cells. We thus anticipate that CTN06 should also have the ability to limit tumor metastasis. However, the genetic characters (e.g., AR and p53 status) of prostate cancer may influence their responses to drug treatment. Further investigation is desired to explore the effect of these factors to the response of prostate cancer cells to CTN06.⁵⁴

In summary, we found that Btk is aberrantly expressed in prostate cancer, which together with Etk present suitable targets for therapy. We have identified a Btk and Etk dual inhibitor, CTN06, with good selectivity toward prostate cancer cells. Further evaluation of its pharmacokinetic and pharmacodynamic properties is underway. Btk and Etk dual inhibition holds exceptional promise as a novel treatment strategy for prostate cancer.

Materials and Methods

Reagents. Purified Etk, Btk, Itk, Mer, Yes, Lyn and Src kinases were obtained from Millipore Inc (Dundee, UK). PI, *N,N*-diisopropylethylamine (DIEA), *N,N*-dimethylformamide (DMF), ethanol, acetonitrile (ACN), *N*-Methyl-2-pyrrolidone (NMP), 1-(3-aminopropyl)piperidine, trifluoroacetic acid (TFA), Pd/C, ammonium formate, cyanogen bromide and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (Saint Louis, MO, USA). L-Leucine methyl ester hydrochloride and 4-(4-pyridinyl)benzoic acid were purchased from Chem-Impex International Inc (Wood Dale, IL, USA). The Annexin V-FITC apoptosis detection kit was obtained from Abcam (Cambridge, MA, USA). Reverse-phase high-performance liquid chromatography (RP-HPLC) from the Waters Corporation (Milford, MA, USA) was used for analysis and purification of CTN06.

Synthesis of CTN06. In brief, a solution of L-leucine methyl ester hydrochloride (545.1 mg, 3.0 mmol) and DIEA (1.15 ml, 6.6 mmol) in DMF (4.5 ml) was added dropwise under vigorous stirring to a solution of 1,5-difluoro-2,4-dinitrobenzene (612.0 mg, 3.0 mmol) in DMF (1.5 ml). The reaction solution was stirred at room temperature for 45 min. This was followed by the addition of a solution of 1-(3-aminopropyl) piperidine (477 μ l, 3.0 mmol) and DIEA (522.6 μ l, 3.0 mmol) in DMF (2 ml). The resulting mixture was agitated at room temperature overnight. Ethanol (60 ml), Pd/C (10%, 600 mg) and ammonium formate (4.5 g, 71.4 mmol) were added to the solution. The solution was heated to reflux for 4 h and then cooled to room temperature. The Pd/C was filtered out and the filtrate

was concentrated with a rotary evaporator. The residue was re-dissolved in ethanol (40 ml), followed by addition of cyanogen bromide (321.3 mg, 3.6 mmol). The resulting mixture was stirred at room temperature for 12 h. The precipitate was collected by filtration and washed with ethanol, three times. The solid was dried in vacuum and used for the next step without further purification. A portion of the solid (382.5 mg, 1.0 mmol) was weighed out and re-dissolved in NMP (1 ml), and was added the solution of 4-(4-pyridinyl)benzoic acid (199.2 mg, 1.0 mmol), HBTU (379.3 mg, 1.0 mmol) and DIEA (348.4 μ l, 2.0 mmol) in NMP (3 ml). The resulting solution was stirred at room temperature overnight. The precipitate was collected by filtration and washed with ethanol followed by RP-HPLC purification. The fraction was collected and lyophilized to give a yellow powder as the final product (Supplementary Figure S1). The homogeneity of the compound was checked by analytical RP-HPLC. The purity was determined to be >95% pure. The identity of the compound was confirmed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry, found: 564.28 Dalton (calculated: 564.31 Dalton for MH⁺).

Cell culture. RWPE1, LNCaP, Du145 and PC3 cells were obtained from ATCC (Manassas, VA, USA) and maintained in RPMI-1640 medium containing 10% fetal bovine serum and 1% penicillin/streptomycin/glutamine.

Tissue microarray. The expression level of Btk in prostate cancer tissue was examined using tissue microarray (PROS-006) from the UC Davis Pathology department. The array was stained with anti-Btk antibody (Santa Cruz Inc., Santa Cruz, CA, USA; sc-1107). The array contains 28 benign, 48 Gleason 6 (CaP 6), 46 Gleason 8 (CaP 8) prostate cancer samples. The expression level of Btk was graded as no, low and high as illustrated in Figure 1a by an expert pathologist.

Btk ELISA. Btk levels in RWPE1, LNCaP, Du145 and PC3 cells were further measured using the Btk ELISA assay kit (Abnova Inc., Littleton, CO, USA; KA2617) according to the manufacturer's protocol.

Reverse transcription and quantitative real-time PCR. Reverse transcription and quantitative real-time PCR (qRT-PCR) were done as described previously.³⁰ Primer sequences used to amplify Btk fragments are listed as follows: forward 5'-GGTGGAGAGCAGAGATAAA-3'; reverse 5'-CCGAGTCATG TGTTTGAATAC-3' (IDT DNA Inc., Coralville, IA, USA). GAPDH was used as the housekeeping gene.

Etk and Btk knockdown assay. Etk and Btk expression in PC3 and RWPE1 cells was knocked down using siRNA. The Btk (Smartpool), Etk (Smartpool) siRNA and non-targeted RNA were obtained from Dharmacon Inc. (Lafayette, CO, USA). The siRNAs were transfected to cells according to the manufacturer's instruction. The expression levels of Btk and Etk were examined using a western blot after 48 h. The growth rates were examined daily using an MTT assay for 3 days. For comparison of SiBtk and LFM-A13, PC3 and Du145 cells were seeded at 5000 cells/well in 96-well plate overnight. Then, the cells were transfected with SiBtk or treated with 50 μ M LFM-A13, cell viability was examined using an MTT assay at 72 h.

Kinase inhibition assay. Kinase inhibition was measured using TLC. Briefly, purified kinases (20 nM), the corresponding substrate (500 μ M, TSFYGRH for Etk, YIYGSFK for the other kinases) and CTN06 (0–10 μ M) were incubated in a kinase reaction (100 mM Hepes, pH 7.4, 10 mM MnCl₂, 10 mM MgCl₂, 1 mM DTT) for 5 min, and the reaction was started by adding 5 μ Ci ³³P-labeled ATP. The reaction (10 μ l) was incubated at room temperature for 1 h and was stopped by adding 10 μ l H₃PO₄. The radioactivity of the peptide substrate was analyzed using TLC as previously described.⁵⁵

Molecular modeling. Molecular docking studies were performed to determine the preferred binding site of CTN06 on the Btk structure. An energy optimized structure of CTN06 was calculated using Merck Molecular Force Field (MMFF) as implemented in Marvin Suite v 5.11 (<http://www.chemaxon.com/products/marvin>). The crystal structure of Btk (PDB ID: 1K2P) that corresponds to amino-acid positions 397–654 was used in our modeling studies. To define a putative binding site for CTN06 on Btk protein structure, we first used a blind docking approach, implemented on the SwissDock web service (<http://swissdock.vital-it.ch>).⁵⁶ Among the clusters generated by SwissDock, the conformation with the lowest binding free energy was selected. To further confirm the binding site predicted by blind docking, we used Autodock v4.2. Btk and

CTN06 structures were prepared for docking using an Autodock Tools package.⁵⁷ Partial atomic charges were assigned to CTN06 using the Gasteiger-Marsili method, and, after the merging of non-polar hydrogens, rotatable bonds were assigned using Autodock Tools. All the water molecules were removed from the Btk structure, and the missing hydrogens and Kollman partial charges were added. Further, non-polar hydrogens were merged to their corresponding carbons, and for each atom the desolvation parameters were assigned. We used a grid size of $60 \times 60 \times 60$ with grid spacing of 0.375 angstroms. The grid size was selected to fit the whole ligand molecule. We used the Lamarckian Genetic Algorithm, called Pseudo Solis-Wets Algorithm, to perform 256 independent docking runs with default parameters in Autodock.⁵⁸ Cluster analysis was performed on docked results using an RMS tolerance of 2 angstroms.

To further understand the stability and dynamics of the ligand-kinase complex, we performed a 20-ns molecular dynamics (MD) simulation, starting with the best-docked structure predicted by Autodock-independent runs. These simulations were performed using NAMD v 2.7b2.⁵⁹ CHARMM27 force fields were used to calculate the potentials of Btk, while CHARMM22 (as implemented in SwissParam, <http://swissparam.ch>)⁶⁰ force fields were used to calculate the potentials of CTN06. The kinase-ligand complex was solvated in a water box with periodic boundary conditions. Dimensions of the water box were selected to be at least 10 angstroms larger than the solute in every direction. The whole system was neutralized with 0.15 M NaCl. An initial minimization step was performed for 6000 steps, followed by 20 ns of relaxation. Trajectories of these simulations were visualized using VMD v 1.9 (<http://www.ks.uiuc.edu/Research/vmd/vmd-1.9/>) and the interactions between the kinase and the ligand were plotted using LigPlot+ v 1.4 and PyMol (<http://www.schrodinger.com/pymol/>).

Western blotting. Western blotting was performed as described previously.⁶¹ Cells were grown in 100 mm dishes to about 50% confluence and treated with vehicle (control) and CTN06 (0.5 and 2 μ M) for 12 h. Proteins were detected by the following antibodies: β -actin (Sigma-Aldrich, A1978), Btk (Santa Cruz Inc., sc-1107), pBtk (pY233, Abcam, ab68217), Etk (Santa Cruz Inc., sc8874), pEtk (pY40, 3211S), Src (2109), pSrc (pY416, 6943), PLC γ 2 (3872), pPLC γ 2 (pY759, 6943), Stat3 (12640), pStat3 (pY705, 4113), ERK (4696) and pERK (4695) were obtained from Cell Signaling Inc. (Beverly, MA, USA). For pBtk and pEtk, cells were pre-treated with 100 μ M pervanadate for 15 min before harvest.

MTT assay. Cells were seeded in 96-well plates and cultured overnight, followed by treatment with 0.1% DMSO, as a vehicle control, and CTN06 at the indicated concentrations for 72 h. Growth inhibition was measured using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Roche Diagnostic, Mannheim, Germany) according to the manufacturer's protocol.

Flow cytometry. PC3 cells were treated with 0.1% DMSO (control) and CTN06 at the indicated concentrations for 24 h. Cell-cycle arrest was determined by the incorporation of propidium iodide (Sigma-Aldrich) into permeabilized cells. Cells undergoing apoptosis were identified using an Annexin V-FITC kit (Abcam), following the manufacturer's instructions. The cells were analyzed using a Coulter Epics XL flow cytometer (Beckman Coulter, Miami, FL, USA).

Microarray assay for miRNAs and cDNAs. PC3 cells were seeded at 10^5 cells/well in 6-well plate and treated with 0.5 μ M CTN06 for 18 h. Cells were harvested and RNA was isolated using a trizol reagent (Ambion Inc., Grand Island, NY, USA). Total RNA samples were submitted to the UC Davis Comprehensive Cancer Center's Genomics Shared Resource (GSR) for microarray profiling of gene and miRNA expression and subsequent data analysis. The methods are briefly described below.

Comprehensive gene expression profiling was performed with Affymetrix GeneChip Human Genome U133 Plus 2.0 (HG-U133 Plus 2.0) (Affymetrix Inc., Santa Clara, CA, USA) arrays according to standard protocols described by the manufacturer. Normalized probe set expression intensities were obtained using robust multi-array average (RMA) for probe summarization and normalization of background-adjusted and log-transformed perfect match probe intensity values. The data set was filtered to retain only those probe sets having expression values that exceeded the 5% lower cutoff threshold in at least one of the samples. Comparison analysis was then performed to identify genes that were differentially expressed between CTN06- and vehicle-treated cells. Criteria for the selection of genes exhibiting significant expression changes included an average fold change of ≥ 2.0 between groups and *P*-values of ≤ 0.05 . Global analysis of miRNA

expression was performed with Agilent Human miRNA Microarrays (Release 16.0) (Agilent Technologies, Santa Clara, CA, USA) as per the manufacturer's standard protocols. Background-subtracted signal intensity values were log-transformed, quantile-normalized and baseline transformed with GeneSpring GX12 software (Agilent Technologies). The data set was then filtered for miRNAs exhibiting ≥ 1.5 -fold differential expression in CTN06-treated cells relative to that of the vehicle-treated controls. The miRNA profile was examined using GeneChip miRNA 2.0 Array (Affymetrix Inc.) and the gene expression profile was examined using cDNA microarray (Affymetrix Inc.) by UC Davis Genome Center.

Autophagy assay. PC3 cells were stably transfected with GFP-LC3, as previously described.³⁰ Cells were grown in a 6-well plate to 50% confluence and treated with 5 μ M CTN06 for 24 h. Autophagy was visualized by GFP-LC3 'puncta' and immunoblot of Endogenous LC3 isoforms under an Olympus BX61 motorized reflected fluorescence microscope with FITC filter (excitation, 480 nm; emission, 535 nm) (Olympus America Inc., Melville, NY, USA) by using the SlideBook4.1 software (Intelligent Imaging Innovations, Denver, CO, USA).

PC3 cell 'wound healing' assay. PC3 cells were grown in 6-well plate to 60% confluency. Then wounds were made using a tip and treated with CTN06 (0 and 0.5 μ M). Cell migration (wound healing) was visualized under microscope at the indicated times.

CTN06 as a chemo-sensitizer. Growth inhibition of CTN06 in combination with 10 μ M CQ, 2 ng/ml DTX or 1 μ M AZD0530 (AZD), to PC3 human prostate cancer cells was evaluated. Cells were seeded at 5000 cells/well in a 96-well plate overnight and pre-treated with the corresponding co-treatments for 1 h, then treated with 0.25 μ M CTN06. The cell viability was measured using an MTT assay after 72 h.

Inhibition of PC3 xenograft tumor growth by CTN06. Animal experimental conditions were in accordance with the protocol approved by the Institutional Animal Care and Use Committee at the University of California, Davis. In all, 2×10^6 PC3 were injected subcutaneously to 5- to 6-week-old male nude mice. Mice were randomly divided into two groups and treated with buffer only (control) or 10 mg/kg/day CTN06 daily starting from 14 days after injection. The size of tumors and body weight were measured once a week. After 42 days treatment, mice were killed and tumors were harvested frozen in liquid nitrogen and stored at -80°C . Paraffin-embedded tumor tissues were sectioned to 5- μ m thickness and mounted on positively charged microscope slides, and 1 mM EDTA (pH 8.0) was used for antigen retrieval. Immunohistochemistry was performed using 1 : 200 dilution of Ki67 antibody (Cell Signaling Inc., 9027) and 1 : 50 dilution of cleaved caspase 3 antibody (Cell Signaling Inc., 9664). Western blots were performed using tumor lysates with LC3 antibody (Cell Signaling Inc., 4599).

Statistics. A one-way ANOVA was used in combination with a Tukey test for pairwise comparison. *P*-values of < 0.05 were considered as significant.

Conflict of Interest

Both KSL and HJK are scientific advisors for C-TAG Inc.

Acknowledgements. This work was in part supported by C-TAG Bioscience Inc (Research grant to RL), NIH grants DOH102-TD-M-111-102001 (to HJK), NSC 102-2320-B-400-018-MY3 (to HJK), and 03A1-MGPP18-014 (to HJK), DK52659 CA150197 (to HJK) and CA098116 (to KSL); DOD Postdoctoral Training Award PC080859 and Auburn Community Cancer Endowment Fund (to WG); DOD Postdoctoral Training Award PC121738 (to GB); and a Stand Up to Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant. This research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T *et al*. Cancer statistics 2008. *CA Cancer J Clin* 2008; **58**: 71–96.
2. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R *et al*. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. *Science* 2007; **318**: 287–290.

3. Honda F, Kano H, Kanegane H, Nonoyama S, Kim ES, Lee SK *et al*. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. *Nat Immunol* 2012; **13**: 369–378.
4. Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S *et al*. Primary B cell immunodeficiencies: comparisons and contrasts. *Annu Rev Immunol* 2009; **27**: 199–227.
5. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA. MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. *J Biol Chem* 2006; **281**: 10489–10495.
6. Khare A, Viswanathan B, Gund R, Jain N, Ravindran B, George A *et al*. Role of Bruton's tyrosine kinase in macrophage apoptosis. *Apoptosis* 2011; **16**: 334–346.
7. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S *et al*. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. *Blood* 2011; **117**: 6287–6296.
8. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potentially enhances bortezomib and lenalidomide activities through NF- κ B. *Cell Signal* 2013; **25**: 106–112.
9. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M *et al*. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. *J Biol Chem* 1999; **274**: 9587–9599.
10. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ *et al*. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. *Blood* 2012; **119**: 2590–2594.
11. Winer ES, Ingham RR, Castillo JJ. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. *Expert Opin Investig Drugs* 2012; **21**: 355–361.
12. Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P *et al*. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. *Arthritis Res Ther* 2011; **13**: R115.
13. Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y *et al*. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. *Blood* 2012; **120**: 1877–1887.
14. Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, Magyar CE *et al*. Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. *PLoS One* 2011; **6**: e17778.
15. Zhang Z, Zhu W, Zhang J, Guo L. Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation. *Cancer Biol Ther* 2011; **11**: 690–698.
16. Guo L, Guo Y, Xiao S. Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. *Oncology* 2007; **72**: 410–416.
17. Xue LY, Qiu Y, He J, Kung HJ, Oleinick NL. Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. *Oncogene* 1999; **18**: 3391–3398.
18. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. *Neoplasia* 2007; **9**: 90–100.
19. Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B *et al*. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. *Cancer Res* 2006; **66**: 8058–8064.
20. Holopainen T, López-Alpuche V, Zheng W, Heljasvaara R, Jones D, He Y *et al*. Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. *Cancer Res* 2012; **72**: 3512–3521.
21. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. *Mol Cell Biol* 2001; **21**: 8385–8397.
22. Chen R, Kim O, Li M, Xiong X, Guan JL, Kung HJ *et al*. Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. *Nat Cell Biol* 2001; **3**: 439–444.
23. Jiang X, Borges RA, McKnight NC, Kaur R, Carpenter CL, Balk SP. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. *J Biol Chem* 2007; **282**: 32689–32698.
24. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. *Proc Natl Acad Sci USA* 1998; **95**: 3644–3649.
25. Jiang T, Guo Z, Dai B, Kang M, Ann DK, Kung HJ *et al*. Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. *J Biol Chem* 2004; **279**: 50181–50189.
26. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J *et al*. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. *Cancer Cell* 2011; **19**: 498–511.
27. Chau CH, Chen KY, Deng HT, Kim KJ, Hosoya K, Terasaki T *et al*. Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. *Oncogene* 2002; **21**: 8817–8829.
28. Lou Y, Owens TD, Kuglstatler A, Kondru RK, Goldstein DM. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. *J Med Chem* 2012; **55**: 4539–4550.
29. Kuglstatler A, Wong A, Tsing S, Lee SW, Lou Y, Villaseñor AG *et al*. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. *Protein Sci* 2011; **20**: 428–436.
30. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT *et al*. Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. *Genes Cancer* 2010; **1**: 40–49.
31. Tsai YT, Su YH, Fang SS, Huang TN, Qiu Y, Jou YS *et al*. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. *Mol Cell Biol* 2000; **20**: 2043–2054.
32. Wang XY, Wu MH, Liu F, Li Y, Li N, Li GY *et al*. Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. *Mol Cell Biochem* 2010; **345**: 283–290.
33. Gattolliat CH, Thomas L, Ciafrè SA, Meurice G, Le Teuff G, Job B *et al*. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. *Br J Cancer* 2011; **105**: 1352–1361.
34. Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J *et al*. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. *Carcinogenesis* 2011; **32**: 1183–1189.
35. Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A *et al*. DNA methylation silences miR-132 in prostate cancer. *Oncogene* 2013; **32**: 127–134.
36. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B *et al*. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. *Blood* 2009; **114**: 2945–2951.
37. Wang WL, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 1 α ,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. *Mol Cancer* 2011; **10**: 58.
38. Zhang Y, Liao JM, Zeng SX, Lu H. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. *EMBO Rep* 2011; **12**: 811–817.
39. Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM *et al*. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. *Clin Cancer Res* 2011; **17**: 7584–7594.
40. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S *et al*. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. *Blood* 2011; **117**: 7053–7062.
41. Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. *Biochem Biophys Res Commun* 2012; **421**: 4–8.
42. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA. ATM is down-regulated by N-Myc-regulated microRNA-421. *Proc Natl Acad Sci USA* 2010; **107**: 1506–1511.
43. Zhang Y, Gong W, Dai S, Huang G, Shen X, Gao M *et al*. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. *Mol Cancer Res* 2012; **10**: 516–522.
44. Dai Y, Siemann DW. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. *BMC Cancer* 2012; **12**: 1–98.
45. Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. *Oncogene* 2010; **29**: 4980–4988.
46. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. *Nature* 1991; **354**: 82–84.
47. McDonald OB, Chen WJ, Ellis B, Hoffman C, Overton L, Rink M *et al*. A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. *Anal Biochem* 1999; **268**: 318–329.
48. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA *et al*. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. *Nat Rev Drug Discov* 2006; **5**: 835–844.
49. Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F *et al*. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. *Cancer Res* 2010; **70**: 5587–5596.
50. Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ *et al*. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. *J Biol Chem* 2001; **276**: 29403–29409.
51. Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D *et al*. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. *Bioorg Med Chem Lett* 2008; **18**: 5916–5919.
52. Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK *et al*. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. *J Clin Oncol* 2005; **23**: 5597–5604.
53. Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. *Mol Cancer Ther* 2010; **9**: 1629–1637.

54. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL *et al*. Molecular characterization of human prostate carcinoma cell lines. *Prostate* 2003; **57**: 205–225.
55. Lou Q, Wu J, Lam KS. A protein kinase assay system for both acidic and basic peptides. *Anal Biochem* 1996; **235**: 107–109.
56. Grosdidier A, Zoete V, Michielin O, Swiss Dock. a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res* 2011; **39**: W270–W277.
57. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS *et al*. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J Comput Chem* 2009; **30**: 2785–2791.
58. Solis FJ, Wets RJB. Minimization by random search techniques. *Math Oper Res* 1981; **6**: 19–30.
59. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E *et al*. Scalable molecular dynamics with NAMD. *J Comput Chem* 2005; **26**: 1781–1802.
60. Zoete V, Cuendet MA, Grosdidier A, Michielin O. SwissParam: a fast force field generation tool for small organic molecules. *J Comput Chem* 2011; **32**: 2359–2368.
61. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. *Oncogene* 1997; **15**: 2705–2716.



Cell Death and Disease is an open-access journal published by **Nature Publishing Group**. This work is licensed under a **Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License**. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

Supplementary Information accompanies this paper on Cell Death and Disease website (<http://www.nature.com/cddis>)